Smoking and outcomes following personalized antiplatelet therapy in chronic coronary syndrome patients: A substudy from the randomized PATH-PCI trial.
Ying PanTing-Ting WuChang-Jiang DengYi YangXian-Geng HouTuo YanShun WangYing-Ying ZhengXiang XiePublished in: Clinical cardiology (2024)
Regardless of smoking, PAT reduced the MACE and MACCE, with no significant difference in bleeding. This suggests that PAT was an recommendable regimen to CCS patients after PCI, taking into consideration both ischemic and bleeding risk.
Keyphrases
- antiplatelet therapy
- end stage renal disease
- acute coronary syndrome
- percutaneous coronary intervention
- coronary artery disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- atrial fibrillation
- prognostic factors
- acute myocardial infarction
- peritoneal dialysis
- heart failure
- coronary artery
- randomized controlled trial
- smoking cessation
- coronary artery bypass grafting
- blood brain barrier
- aortic stenosis
- st elevation myocardial infarction
- brain injury
- left ventricular
- subarachnoid hemorrhage
- transcatheter aortic valve replacement